Pricing Log in Create free account
Saturday 17 October 2026 Export MTVA’s income statement to Excel — free account

MetaVia Inc.

MTVA Healthcare Biotechnology

In the quarter to June 2026, EPS grew 68.5% and free cash flow fell 22.4%, each against the same quarter a year earlier.

1.26 0.11 −8.03%
Market cap
$9.0M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 19.25%

Capital & Financial Ratios $m

Market Cap 9.03
Revenue —
Net Income (14.45)
Free Cash Flow (15.83)
Net Debt (12.63)
Current Ratio 2.06 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E —
P/S ratio 0.00
P/B ratio 1.10
Past 5Y EPS Growth —
This Y EPS Growth 65.76% (at or above 15%: strong)
Next Y EPS Growth 5.83%
Next Y revenue growth —
Next 5Y EPS Growth 39.14% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 20.38%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2021 Powerpack
2020 Powerpack
2019 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 22 16 10 13
Receivables — — — —
Inventory — — — —
Other — — — —
23 16 11 13
2023 2024 2025 Q'26
Payables 2 5 4 3
ST’ Debt — — — —
Other 1 0 0 0
6 8 6 6

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (5.83%) (37.41%)

Revenue $m

Year
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (4) — — —
’25 (5) (3) (3) (5) (16)
’24 (6) (7) (6) (5) (25)
’23 (3) (2) (3) (3) (11)
’22 (5) (3) (2) (2) (12)
’21 (6) (4) (3) (3) (15)
’20 (4) (2) (2) (2) (11)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (4) — — —
’25 (5) (3) (3) (5) (16)
’24 (6) (7) (6) (5) (25)
’23 (3) (2) (3) (3) (11)
’22 (5) (3) (2) (2) (12)
’21 (6) (4) (3) (3) (15)
’20 (4) (2) (2) (2) (11)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.79) (0.90) — — —
’25 (3.96) (2.86) (1.54) 0.98 (7.35)
’24 (14.52) (20.35) (6.05) 1.85 (39.16)
’23 (5.28) (1.76) (7.92) (11.52) (27.06)
’22 (290.72) (317.15) (308.03) 442.60 (477.89)
’21 (396.44) (475.72) (422.86) (449.29) (1.74k)
’20 (792.87) (396.44) (502.15) (3.17k) (4.84k)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 478,500.00 475,200.00 37,620.00 15,708.00 12,724.80 3,168.00 48.49 31.77 16.61 6.05

Analyst estimates 2026–2028

Powerpack
High 922,680.00 1,424,940.00 754,380.00 98,010.00 79,200.00 20,087.76 5,618.80 83.60 74.25 30.25
People
People Employees 114 18 9 12 7 5 2 8 9 8
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income, $m
Income, $m Revenue — — — — — — — — — —
Gross margin, % — — — — — — — — — —
EBT (15) (33) (16) (21) (30) (15) (14) (12) (28) (13)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net income (15) (33) (16) (21) (30) (15) (14) (12) (28) (13)
Depreciation — — — 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings (169,806.80) (213,414.70) (9,654.60) (10,783.06) (4,836.52) (1,744.32) (477.89) (27.06) (39.16) (7.35)
Cash flow (110,430.00) (134,505.00) (9,031.87) (3,519.50) (1,764.59) (1,719.77) (399.73) (23.43) (35.04) (8.89)
Capex 0.00 0.00 (1.87) (107.00) (0.66) (0.34) 0.27 (0.11) (0.01) 0.00
Free cash flow (110,430.00) (134,505.00) (9,033.75) (3,626.50) (1,765.25) (1,720.11) (399.45) (23.53) (35.05) (8.89)
Book value 206,320.00 19,705.00 (8,303.75) 6,146.00 1,180.82 1,658.75 742.32 36.19 11.25 3.02
Shares, m 0 0 0 0 0 0 0 0 1 2
Valuation, ×
Valuation, × P/E — — — — — — — — — —
P/S — — — — — — — — — —
P/B — — — — — — — — — —
EV/Sales — — — — — — — — — —
EV/FCF — — — — — — — — — —
Cash, $m
Cash, $m Operating cash flow (11) (27) (14) (7) (11) (15) (12) (11) (25) (16)
Capex — — 0 0 0 0 0 0 0 0
Free cash flow (11) (27) (14) (7) (11) (15) (12) (11) (25) (16)
Balance, $m
Balance, $m Working capital 21 13 4 12 7 14 22 17 8 5
Total debt — 10 0 — — — — — — —
Net debt (24) (8) (3) (14) (10) (16) (33) (22) (16) (10)
Shareholders’ equity 21 4 (13) 12 7 15 22 17 8 5
Returns, %
Returns, % ROA (102.26) (152.68) (136.00) (233.07) (233.35) (110.09) (55.50) (44.29) (141.35) (94.75)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE (362.38) (271.97) 332.28 4,279.52 (304.47) (140.22) (76.85) (64.89) (224.18) (195.61)
Negative figures in brackets.

All 10 years →

Charts ten years each

MetaVia Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TOVX Theriva Biologics, Inc. $9.7M 0.1× — +33.08% (above 0%: growing) n/m +34.69% (above 0%: growing) 100.00% 0.00% Compare
BIVI BioVie Inc. $9.6M — (loss-making) — — n/m +26.50% (above 0%: growing) 0.00% 0.00% Compare
LSTA Lisata Therapeutics, Inc. $9.6M — (loss-making) — (loss-making) −98.30% (below 0%: shrinking) n/m +33.04% (above 0%: growing) 100.00% 0.00% Compare
VTGN VistaGen Therapeutics, Inc. $9.5M — (loss-making) — (loss-making) +504.92% (above 0%: growing) n/m +22.23% (above 0%: growing) 100.00% (904.34%) Compare
CMMB Chemomab Therapeutics Ltd. Sponsored ADR $9.4M — (loss-making) — — n/m +47.89% (above 0%: growing) 0.00% 0.00% Compare
MTVA MetaVia Inc. $9.0M — (loss-making) — — n/m −22.42% (below 0%: shrinking) — 0.00%
JAGX Jaguar Animal Health, Inc. $8.9M 0.0× — (loss-making) −58.88% (below 0%: shrinking) n/m +13.83% (above 0%: growing) 15.84% (620.16%) Compare
NKGN NKGen Biotech, Inc. $8.8M — (loss-making) — — n/m +28.68% (above 0%: growing) 100.00% 0.00% Compare
CSCIF COSCIENS Biopharma Inc. $8.6M 1.0× — +30.04% (above 0%: growing) n/m +113.30% (above 0%: growing) 55.27% 13.43% Compare
Median of peers $9.4M 0.1× — +30.04% — +30.86% 77.64% 0.00%

All 614 Biotechnology stocks →

MetaVia Inc. (MTVA) key facts

  • MetaVia Inc. (MTVA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, MTVA traded at $1.26, a market capitalization of $9.0 million.
  • Return on equity was −195.6% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.

MetaVia Inc. (MTVA) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/MTVA · For information only; not investment advice. · © 2026 stockrow.com